PH12019502361A1 - ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF - Google Patents

ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Info

Publication number
PH12019502361A1
PH12019502361A1 PH12019502361A PH12019502361A PH12019502361A1 PH 12019502361 A1 PH12019502361 A1 PH 12019502361A1 PH 12019502361 A PH12019502361 A PH 12019502361A PH 12019502361 A PH12019502361 A PH 12019502361A PH 12019502361 A1 PH12019502361 A1 PH 12019502361A1
Authority
PH
Philippines
Prior art keywords
n3pglu
amyloid beta
beta peptide
peptide antibodies
antibodies
Prior art date
Application number
PH12019502361A
Other languages
English (en)
Inventor
Ronald Bradley Demattos
Jirong Lu
Ying Tang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH12019502361A1 publication Critical patent/PH12019502361A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PH12019502361A 2017-04-20 2019-10-17 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF PH12019502361A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762487550P 2017-04-20 2017-04-20
PCT/US2018/027718 WO2018194951A1 (en) 2017-04-20 2018-04-16 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
PH12019502361A1 true PH12019502361A1 (en) 2020-07-13

Family

ID=62111232

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019502361A PH12019502361A1 (en) 2017-04-20 2019-10-17 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Country Status (28)

Country Link
US (3) US10647759B2 (enExample)
EP (1) EP3612559A1 (enExample)
JP (3) JP6900500B2 (enExample)
KR (2) KR102352670B1 (enExample)
CN (2) CN117024583A (enExample)
AR (1) AR111208A1 (enExample)
AU (2) AU2018255221B2 (enExample)
BR (1) BR112019018810A2 (enExample)
CA (1) CA3058482C (enExample)
CL (1) CL2019002922A1 (enExample)
CO (1) CO2019011349A2 (enExample)
CR (1) CR20190445A (enExample)
DO (1) DOP2019000241A (enExample)
EA (1) EA201992163A1 (enExample)
EC (1) ECSP19075146A (enExample)
IL (1) IL269003B2 (enExample)
JO (1) JOP20190247A1 (enExample)
MA (1) MA50144A (enExample)
MX (2) MX2019012445A (enExample)
NZ (1) NZ758066A (enExample)
PE (1) PE20200011A1 (enExample)
PH (1) PH12019502361A1 (enExample)
SA (1) SA519410311B1 (enExample)
SG (1) SG11201909022PA (enExample)
TW (2) TWI705975B (enExample)
UA (1) UA126806C2 (enExample)
WO (1) WO2018194951A1 (enExample)
ZA (1) ZA202007868B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
US11236155B2 (en) 2019-03-26 2022-02-01 Janssen Pharmaceutica Nv Antibodies to pyroglutamate amyloid-β and uses thereof
WO2021151011A2 (en) * 2020-01-24 2021-07-29 The Board Of Trustees Of Western Michigan University Treatment of neurodegenerative proteinopathies using fas apoptosis inhibitory molecule (faim) or a fragment and/or a mimetic thereof
US20230406914A1 (en) 2020-10-02 2023-12-21 Eli Lilly And Company Methods for reducing host cell protein content in antibody purification processes and antibody compositions having reduced host cell protein content
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
JP7306746B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
JP7268910B2 (ja) * 2021-09-16 2023-05-08 株式会社ユニバーサルエンターテインメント 遊技機
JP7306745B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
MX2024004514A (es) * 2021-10-22 2024-05-07 Lilly Co Eli Terapia de combinacion con el inhibidor de o-glcnacasa (oga).
KR20240105403A (ko) 2021-10-29 2024-07-05 일라이 릴리 앤드 캄파니 인터류킨-34를 표적화하는 화합물 및 방법
US11976114B2 (en) * 2021-10-29 2024-05-07 Eli Lilly And Company Compounds and methods targeting interleukin-34
AU2022376930A1 (en) * 2021-10-29 2024-05-02 Eli Lilly And Company Compounds and methods targeting interleukin-34
WO2023077042A1 (en) 2021-10-29 2023-05-04 Eli Lilly And Company Compounds and methods targeting interleukin-34
KR20240145486A (ko) 2022-02-03 2024-10-07 일라이 릴리 앤드 캄파니 알츠하이머병을 진단 및 치료하기 위한 국소 타우 영상화
CN117327168A (zh) * 2022-06-24 2024-01-02 厦门大学 B2M-GluN1封闭肽、其药物组合物及用途
JP2025540659A (ja) * 2022-11-17 2025-12-16 イーライ リリー アンド カンパニー 抗Ｎ３ｐＧｌｕアミロイドベータ抗体、用量、及びその使用
WO2024133925A1 (en) 2022-12-22 2024-06-27 Bioarctic Ab Antibody which binds to abetape3
WO2025106313A1 (en) 2023-11-14 2025-05-22 Eli Lilly And Company Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES
CN118459583B (zh) * 2024-07-11 2024-09-10 齐鲁制药有限公司 抗N3pGlu淀粉样蛋白β抗体及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062801A2 (en) * 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
AU2003250102B2 (en) 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
CA2575663C (en) 2004-07-30 2013-04-23 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
UY29504A1 (es) * 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
PL2468770T3 (pl) 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
KR20110036809A (ko) 2008-06-12 2011-04-11 아피리스 아게 파킨슨병과 관련된 증상을 치료하기 위한 화합물
EP2321348A2 (en) 2008-07-09 2011-05-18 University of Zürich Method of promoting neurogenesis
EA028427B1 (ru) 2008-07-21 2017-11-30 Пробиодруг Аг АНТИТЕЛО, СВЯЗЫВАЮЩЕЕСЯ С Aβ-ПЕПТИДАМИ ИЛИ ИХ ВАРИАНТАМИ, КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО, И ЕГО ПРИМЕНЕНИЕ
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
WO2012021475A2 (en) 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
PT3042917T (pt) * 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
WO2015175769A1 (en) * 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
AU2016248946C1 (en) * 2015-04-13 2024-10-17 Pfizer Inc. Therapeutic antibodies and their uses
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
JOP20190247A1 (ar) 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها

Also Published As

Publication number Publication date
JOP20190247A1 (ar) 2019-10-20
US20180305444A1 (en) 2018-10-25
US20200262902A1 (en) 2020-08-20
UA126806C2 (uk) 2023-02-08
TW202120541A (zh) 2021-06-01
MX2022011817A (es) 2022-10-10
AU2021203927A1 (en) 2021-07-08
CN110582511A (zh) 2019-12-17
SA519410311B1 (ar) 2022-03-20
TWI705975B (zh) 2020-10-01
CR20190445A (es) 2019-11-06
EP3612559A1 (en) 2020-02-26
JP6900500B2 (ja) 2021-07-07
MA50144A (fr) 2020-07-29
CO2019011349A2 (es) 2019-10-31
BR112019018810A2 (pt) 2020-05-05
CN110582511B (zh) 2023-08-08
JP2021151253A (ja) 2021-09-30
JP2020510081A (ja) 2020-04-02
MX2019012445A (es) 2020-01-13
US20210371509A1 (en) 2021-12-02
IL269003B1 (en) 2025-06-01
IL269003A (en) 2019-10-31
SG11201909022PA (en) 2019-11-28
US11078261B2 (en) 2021-08-03
WO2018194951A1 (en) 2018-10-25
TW201902924A (zh) 2019-01-16
TWI789644B (zh) 2023-01-11
DOP2019000241A (es) 2019-10-15
CA3058482A1 (en) 2018-10-25
AU2021203927B2 (en) 2024-03-21
NZ758066A (en) 2022-10-28
IL269003B2 (en) 2025-10-01
AU2018255221B2 (en) 2021-07-01
JP2023058623A (ja) 2023-04-25
KR20220011800A (ko) 2022-01-28
EA201992163A1 (ru) 2020-03-02
ECSP19075146A (es) 2019-10-31
CN117024583A (zh) 2023-11-10
KR102567295B1 (ko) 2023-08-16
CL2019002922A1 (es) 2020-03-13
CA3058482C (en) 2023-05-09
PE20200011A1 (es) 2020-01-06
KR102352670B1 (ko) 2022-01-19
AU2018255221A1 (en) 2019-09-19
AR111208A1 (es) 2019-06-12
US10647759B2 (en) 2020-05-12
JP7227312B2 (ja) 2023-02-21
JP7532571B2 (ja) 2024-08-13
KR20190129100A (ko) 2019-11-19
ZA202007868B (en) 2023-06-28

Similar Documents

Publication Publication Date Title
PH12019502361A1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
ZA201803396B (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
IL285782A (en) Compounds, compositions, and methods for treating disease
IL293783A (en) Compounds and compositions for treating hematological disorders
IL264049A (en) Compounds, preparations and methods for treating the disease
PH12013500277A1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
HUE060711T2 (hu) Makrociklusos vegyületek betegségek kezelésére
WO2014124334A3 (en) Transthyretin antibodies and uses thereof
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE
MY184890A (en) Improved a? protofibril binding antibodies
EP3684418C0 (en) COMPOUNDS FOR THE TREATMENT OF CYSTEAMINE-RESPONSIVE DISORDERS
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use
LT3687567T (lt) Anti-adrenomedulino rišiklis, skirtas panaudoti taikant ligos simptomų terapiją arba profilaktiką
CO2017001087A2 (es) Anticuerpos anti proteína similar a angiopoyetina 4
EP3820477A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
EP3672593C0 (en) DRUGS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO VASOCONSTRICTION
GB201911728D0 (en) Bacterial composistions for the treatment of disease
GB201814346D0 (en) Diagnosis of disease
TN2013000045A1 (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
HK1241393A1 (en) Humanized anti-hepcidin antibodies and uses thereof
TH1501007171A (th) แอนติ-vegf แอนติบอดีและองค์ประกอบทางเภสัชกรรมสำหรับป้องกัน วินิจฉัย หรือรักษามะเร็ง หรือโรคที่เกี่ยวข้องกับการสร้างหลอดเลือดที่ประกอบด้วยสิ่งเดียวกัน
GB201616502D0 (en) The use of brain waves as biomarkers for alzheimers disease and combined treatment for early stage diagnosed patients
BR112017021416A2 (pt) anticorpos anti-flt-1 no tratamento de displasia broncopulmonar.